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Abstract
Background: Infections caused by community-associated strains of methicillin-resistant Staphylococcus aureus (CA-
MRSA) are associated with a marked and prolonged host inflammatory response. In a sepsis simulation model, we
tested whether the anesthetic ketamine inhibits the macrophage TNF response to antibiotic-exposed CA-MRSA
bacteria via its antagonism of N-methyl-D-aspartate (NMDA) receptors. RAW264.7 cells were stimulated for 18 hrs
with 10
5 to 10
7 CFU/mL inocula of either of two prototypical CA-MRSA isolates, USA300 strain LAC and USA400
strain MW2, in the presence of either vancomycin or daptomycin. One hour before bacterial stimulation, ketamine
was added with or without MK-801 (dizocilpine, a chemically unrelated non-competitive NMDA receptor
antagonist), APV (D-2-amino-5-phosphono-valerate, a competitive NMDA receptor antagonist), NMDA, or
combinations of these agents. Supernatants were collected and assayed for TNF concentration by ELISA.
Results: RAW264.7 cells exposed to either LAC or MW2 in the presence of daptomycin secreted less TNF than in
the presence of vancomycin. The addition of ketamine inhibited macrophage TNF secretion after stimulation with
either of the CA-MRSA isolates (LAC, MW2) in the presence of either antibiotic. The NMDA inhibitors, MK-801 and
APV, also suppressed macrophage TNF secretion after stimulation with either of the antibiotic-exposed CA-MRSA
isolates, and the effect was not additive or synergistic with ketamine. The addition of NMDA substrate augmented
TNF secretion in response to the CA-MRSA bacteria, and the addition of APV suppressed the effect of NMDA in a
dose-dependent fashion.
Conclusions: Ketamine inhibits TNF secretion by MRSA-stimulated RAW264.7 macrophages and the mechanism
likely involves NMDA receptor antagonism. These findings may have therapeutic significance in MRSA sepsis.
Background
Infections caused by community-associated strains of
methicillin-resistant Staphylococcus aureus (CA-MRSA)
present a major public health problem because of recent
increases in the incidence of these infections [1,2]. In a
2007 report, the Centers for Disease Control concluded
that Staphylococcus aureus is now the most important
cause of serious and fatal infection in the United States
[3]. The prototypical USA400 strain, MW2, (CDC
nomenclature for this strain of MRSA) was first isolated
in 1999 from a Midwest child with fatal CA-MRSA
pneumonia [4]. In 2003, the prototypical USA300 CA-
MRSA strain, LAC, was isolated from Los Angeles
County patients with skin and soft tissue infections,
severe pneumonia and sepsis. Recently, concerns about
CA-MRSA infections were heightened after reports of
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patients infected with the novel 2009 H1N1 influenza A
virus [5,6].
CA-MRSA isolates express many virulence factors
[7,8], including several cytolysins: a-toxin, g-toxin,
Panton-Valentine leukocidin (PVL), phenol-soluble
modulins (PSMs), δ-toxin and, unlike traditional
hospital-associated (HA-MRSA) isolates, may express
superantigens such as TSST-1 [9]. These bacterial
components can stimulate massive cytokine release
and lead to septic shock, acute respiratory distress syn-
drome (ARDS) and death. It is likely that strategies
designed to modulate the excessive and prolonged host
inflammatory response could improve the outcome of
fulminant MRSA infections.
Monocytes and macrophages play important roles in
host defense against staphylococci and other pyogenic
bacteria [10], but excessive systemic or local production
of inflammatory mediators by macrophages could be
deleterious in patients with severe staphylococcal infec-
tions. We previously reported that RAW264.7 murine
macrophages exposed to any of a series of six pediatric
clinical isolates of S. aureus (two CA-MRSA, two HA-
MRSA, and two methicillin-susceptible strains) in the
presence of daptomycin (vs. vancomycin) secreted less
TNF and accumulated less inducible nitric oxide
synthase (iNOS) protein [11]. Vancomycin is a cell-wall
active antibiotic that triggers bacterial lysis; it is the anti-
biotic most commonly used to treat severe MRSA infec-
tions in children [12]. Daptomycin is a novel antibiotic
that is rapidly bactericidal against staphylococci but
does not appear to cause rapid bacterial lysis; the
mechanism of its action is not certain but it is reported
to trigger depolarization of the bacterial membranes and
inhibition of both DNA and RNA synthesis [13,14]. The
rapid lysis of staphylococci, streptococci and other pyo-
genic bacteria exposed to cell-wall active antibiotics
such as beta-lactams and vancomycin results in exagger-
ated release of bacterial products and an augmented and
potentially harmful host inflammatory response [15,16].
Therefore, optimal treatment of sepsis and other severe
bacterial infections might include the use of antibiotics
and/or other medications that blunt the host inflamma-
tory response and dampen the cytokine cascade [16].
Ketamine is one of the recommended anesthetics in
pediatric septic shock [17-19], which is frequently
caused by staphylococci [12,20]. The reasoning for keta-
mine’s use in staphylococcal septic shock is its blood
pressure supporting effect. It increases cardiac output
and blood pressure, possibly via a catecholamine release
mechanism [17,21]. Some data suggest that ketamine
has anti-inflammatory effects [22-25]. For example, it
has been reported that ketamine suppresses macrophage
TNF secretion in response to Gram-negative bacterial
LPS in vivo and in vitro [22,23,25]. There is also one
report that ketamine suppresses TNF production by
human whole blood in vitro after exposure to staphylo-
coccal enterotoxin B [24]. The mechanisms responsible
for the anti-inflammatory effects of ketamine are not
known [22-25].The present study examined the hypoth-
esis that ketamine could suppress macrophage TNF pro-
duction in response to whole bacteria, in this case
clinical isolates of methicillin-resistant Staphylococcus
aureus (MRSA). Given the important role of TNF in
sepsis [26-29], and the importance of staphylococcal
sepsis in children, such suppression could have a thera-
peutic impact.
Although membrane-bound Toll-like receptors (TLR2
and TLR4) are essential for lipopolysaccharide (LPS)-
induced TNF production [30], this is not the case for
Staphylococcus aureus. Because S. aureus is able to
“attack” or form pores in macrophages, TNF secretion
occurs even in the absence of TLR 2 and TLR4 sensors
(possibly via Nod1 and Nod2, intracytoplasmic sensors
of peptidoglycan-derived muropeptides) [31]. Therefore,
another mechanism independent of Toll-like receptors
must exist for ketamine’s anti-inflammatory action, at
least in staphylococcal infections.
We also tested the effects of two chemically unrelated
NMDA receptor antagonists, the anti-convulsant MK-
801 (dizocilpine) [32,33], a non-competitive inhibitor of
NMDA receptors, and APV (D-2-amino-5-phosphono-
valerate), a competitive NMDA receptor antagonist
[34,35], as well as the NMDA substrate itself, on macro-
phage TNF secretion in response to antibiotic-treated
CA-MRSA bacteria.
Methods
Bacteria
For these studies, we utilized two well-characterized
clinical isolates: LAC (Los Angeles County), representa-
tive of the USA300 group of organisms and closely
related to the dominant CA-MRSA clone associated
with soft tissue infections and serious invasive disease in
the Memphis area [1], and MW2, a clinical isolate from
a midwestern child with fatal CA-MRSA sepsis [4],
representative of the USA400 group of organisms that
constitute the other main lineage of CA-MRSA isolates
in the United States.
Bacteria were grown to late logarithmic phase at 37°C
in tryptic soy broth (Becton Dickinson and Co., Sparks,
MD) and washed three times in endotoxin-free phos-
phate-buffered saline. Concentrations were determined
by colony counts. A range of concentrations of bacteria
(10
5-10
7 CFU/mL) was studied, based upon our pre-
viously published data with other CA-MRSA strains [11]
and our preliminary experiments using LAC and MW2
(data not shown).
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strains were determined by the microbiology laboratory
at Le Bonheur Children’s Hospital using the E-test
method: both strains were fully susceptible to vancomy-
cin and daptomycin (LAC: MIC vancomycin 1.0 μg/mL;
daptomycin 0.75 μg/mL; MW2: MIC vancomycin < 0.5
μg/mL; daptomycin 0.75 μg/mL).
Cell culture
RAW264.7 murine macrophage-like cells were pur-
chased from the ATCC and cultured in Dulbecco’s
modified Eagle’s medium (Mediatech Inc., Herndon,
VA) supplemented with 10% fetal bovine serum
( H y C l o n e ,L o g a n ,U T )a n d2m Mg l u t a m i n e( G I B C O ,
Carlsbad, CA). Experiments were done in 24-well tissue
culture plates (Becton Dickinson, Lincoln Park, NJ) with
1×1 0
6 cells per well.
Either vancomycin or daptomycin was added to the
cell cultures immediately before the addition of live sta-
phylococci (10
5-10
7 CFU/mL). Cells were then incu-
bated for 18 hours. Daptomycin was obtained from
Cubist Pharmaceuticals (Lexington, MA). Vancomycin
was purchased via the Department of Pharmacy at Le
Bonheur Children’s Hospital (LBCH) from Hospira
(Lake Forest, IL). Clinically achievable concentrations of
each of the antibiotics, as previously tested in our
laboratory [11], were used (20 μg/mL).
These experiments were repeated in parallel in the pre-
sence of ketamine (100 μM) and/or MK-801 (dizocilpine,
150 μM), APV (D-2-amino-5-phosphonovalerate, 300 μM
("low”) or 3 mM ("high”), or NMDA (30 μM). The modula-
tion of MRSA-stimulated macrophage TNF production by
ketamine was subsequently examined also at a range of
concentrations of 10 μΜ,5 0μΜ,1 0 0μΜ and 150 μΜ.
The selected concentration (100 μM) is based on the
achievable anesthetic concentrations [36-39] and on the
pre-existing literature related to ketamine’s TNF suppres-
sive effect on murine macrophage models when stimulated
by LPS [23-25,27]. The concentrations for the other factors
were selected from the available literature, MK-801 [40-42],
APV and NMDA [32] have previously been studied in cell
culture models and have been shown to not cause cytotoxi-
city at the tested concentrations. Ketamine and/or MK-801
or APV or NMDA were added to the macrophage cultures
one hour prior to bacterial challenge. The source of keta-
mine was Ketalar
®, a racemic mixture (1:1) of optically
active isomers (R and L) of this drug, purchased from the
LBCH pharmacy. Emphasis in the experiment was placed
on correlation with the clinical situation; thus racemic keta-
mine, the most commonly clinically used product, was
selected. Dizocilpine (MK-801), APV and NMDA were
purchased from Sigma Chemical Co. (St. Louis, MO).
After incubation, cell-free supernatants were collected
and assayed for TNF concentrations by using a solid-
phase sandwich enzyme-linked immunosorbent assay as
specified by the manufacturer (eBioscience, San Diego,
CA). TNF is a key cytokine produced by macrophages
during MRSA stimulation. In our preliminary studies,
we also measured secretion of other cytokines and
found that IL-1, IL-6, and NO secretion were strongly
correlated with TNF secretion in response to these bac-
teria (r
2 = 0.84, 0.87 and 0.93, respectively). We focused
on TNF secretion for these studies.
The tested concentrations of vancomycin, daptomycin,
ketamine, MK-801, APV, and NMDA had no effect on
the viability of the RAW264.7 cells, as determined by
visual inspection of the monolayer, low power micro-
scopic inspection of the monolayer and exclusion of
0.2% trypan blue dye.
For the single comparison experiments (ketamine or MK
801 or APV), TNF secretion measurements were validated
with an average of at least three well replicates and each of
the experiments was repeated at least three times (a total of
at least nine samples). The four preliminary runs and all the
exposures (total of 16) where the inocula were different
from 10
5 to10
7 CFUs/mL at the verifying colony count
were excluded from the final analysis. Experiments with dif-
ferent exposure times (6, 10, 14, 24 hours) were conducted
to determine whether the inhibition increased over time. In
the multiple comparison experiments (ketamine and MK
801 synergistic action), TNF was measured from at least
four well replicates. All experiments were performed sepa-
rately for LAC and for MW2 MRSA strains. There is an
intrinsic experimental variation of absolute values of TNF
production (up to 25%) because of cell culture and macro-
phage growth characteristics.
Data analysis
The design was composed of factorial multiple measure-
ments and the results were analyzed according to a
mixed linear model, (GLIMMIX) SAS 9.2 (SAS Institute,
Cary, NC) and R 2.9.1 and ggplot2 software. We set
pre-planned (a priori) contrasts, i.e., we set all our com-
parisons in advance of multiple setting experiments. Sig-
nificant differences were presumed at a probability value
of p < 0.05. The results were graphed using error bars
with 95% confidence intervals. Differences in the means
were estimated either with asymptotic techniques for
normally distributed data or bootstrapping techniques
for non-normally distributed data.
Results
CA-MRSA strains MW2 and LAC stimulated less TNF
secretion by RAW264.7 murine macrophages in the
presence of daptomycin than in the presence of
vancomycin
As previously observed with two USA300 CA-MRSA
strains isolated from Memphis children with invasive
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Page 3 of 9staphylococcal infections [11], macrophages exposed to
either of the two prototypical CA-MRSA strains studied
(the USA300 strain, LAC, or the USA400 strain, MW2)
secreted significantly less TNF in the presence of dapto-
mycin as compared with vancomycin (more than 50%
reduction in each strain; Figure 1). Macrophage TNF
secretion in response to MW2 was 34,535 ± 1,536 pg/
mL in the presence of vancomycin and 15,377 ± 1,267
pg/mL in the presence of daptomycin, a reduction of
55%, significant at p < 0.05. Similarly, macrophage TNF
secretion in response to LAC in the presence of vanco-
mycin was 33,345 ± 1,535 pg/mL, and 14,432 ± 1,536
pg/mL in the presence of daptomycin, a reduction of
57%, significant at p < 0.05. We previously reported
similar findings in six S. aureus clinical isolates (includ-
ing two pediatric CA-MRSA isolates of the USA300
group), suggesting that this effect of daptomycin is con-
served in many different S. aureus isolates.
Ketamine inhibited TNF secretion by murine
macrophages stimulated with CA-MRSA isolates in the
presence of antibiotics
The addition of ketamine (100 μΜ) to macrophage cell
cultures inhibited TNF secretion in response to vanco-
mycin- or daptomycin-exposed CA-MRSA isolates
(Figure 2). The effect was similar on both strains, LAC
and MW2, in the presence of vancomycin (upper panel)
or daptomycin (lower panel).
In the initial experiments we analyzed the effect of
one hour pre-incubation with ketamine on the macro-
phage response to vancomycin-exposed CA-MRSA
bacteria (MW2 and LAC). In response to vancomycin-
exposed MW2, pre-incubation with ketamine reduced
macrophage TNF secretion by approximately 29% (p <
0.05), i.e., from 33,085 ± 867 pg/mL to 23,347 ± 862
pg/mL. Pre-incubation with ketamine led to a similar
reduction (25%; p < 0.05) in macrophage TNF secre-
tion response after stimulation with vancomycin-
exposed LAC (from 28,365 ± 735 pg/mL to 21,432 ±
736 pg/mL).
We next studied the effect of ketamine pre-incuba-
tion on macrophage TNF secretion after stimulation
with daptomycin-exposed MW2 or LAC. Once again,
the addition of ketamine resulted in significant inhibi-
tion of macrophage TNF secretion in response to
MW2 (23,185 ± 1,267 pg/mL to 17,354 ± 853 pg/mL,
a reduction of approximately 25%; p <0 . 0 5 )o rL A C
(approximately 18% reduction, p < 0.05; Figure 2).
Adding ketamine after the MRSA inocula did not alter
the response.
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Figure 1 The CA-MRSA isolates LAC (USA300) and MW2
(USA400) stimulated less TNF secretion by RAW264.7 murine
macrophages when exposed to daptomycin (DAP) than when
exposed to vancomycin (VAN). LAC or MW2 were added to
RAW264.7 cells at a final concentration of 10
5 to 10
7 CFU/mL
(retrospective confirmation) in the presence of either vancomycin or
daptomycin at 20 μg/mL. Cells were incubated for 18 hours;
supernatants were collected and analyzed for TNF content by an
enzyme-linked immunosorbent assay (ELISA). Results are depicted as
means with 95% confidence intervals shown as “error bars” (See
Methods). The “*” indicates significance at p < 0.05. Control
represents the mean TNF macrophage production by macrophages
not stimulated with bacteria.
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Figure 2 Ketamine inhibited TNF secretion by RAW264.7
murine macrophages stimulated with antibiotic-treated CA-
MRSA isolates LAC and MW2. LAC or MW2 were added to
RAW264.7 cells at a final concentration of 10
5 to 10
7 CFU/mL
(retrospective confirmation) in the presence of either vancomycin at
20 μg/mL (upper panel) or daptomycin at 20 μg/mL (lower panel).
One hour prior to stimulation, ketamine (100 μM) was added to the
indicated wells. Cells were then incubated for 18 hours;
supernatants were collected and analyzed for TNF content by ELISA.
Results are depicted as means with 95% confidence intervals shown
as “error bars” (See Methods). The “*” indicates significance at p <
0.05. Control represents the mean TNF macrophage production by
macrophages not stimulated with bacteria.
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macrophage TNF secretion after stimulation with
antibiotic-exposed CA-MRSA strains
Pre-incubation of RAW264.7 cells for one hour with the
NMDA receptor antagonist, MK-801 (150 μΜ), also
inhibited TNF secretion by these cells after stimulation
with antibiotic-exposed CA-MRSA strains (MW2 or
LAC, Figure 3). In response to stimulation with MW2
in the presence of vancomycin, pre-incubation with
MK-801 significantly inhibited TNF secretion by these
cells, i.e., from 32,407 ± 1,188 pg/mL to 23,337 ± 1,272
pg/mL (approximately 28% reduction; p < 0.05, Figure 3,
upper panel). MK-801 also inhibited macrophage TNF
secretion in response to vancomycin-exposed LAC,
causing a 34% reduction (Figure 3, upper panel).
Pre-incubation with MK-801 also significantly inhib-
ited macrophage TNF secretion in response to daptomy-
cin-treated MW2 or LAC (Figure 3, lower panel). In
response to stimulation with MW2 in the presence of
daptomycin, pre-incubation with MK-801 inhibited TNF
secretion by these cells by approximately 26% (from
22,305 ± 648 pg/mL to 16,437 ± 642 pg/mL, p <0 . 0 5 ) .
MK-801 inhibited macrophage TNF secretion in
response to daptomycin-exposed LAC by approximately
33% (from 22,164 ± 864 pg/mL to 14,647 ± 832 pg/mL,
p < 0.05).
No additive or synergistic inhibition of macrophage TNF
secretion is observed after pre-incubation with ketamine
plus MK-801
Pre-incubation of RAW264.7 cells with combinations
of MK-801 and ketamine did not affect the magnitude
of inhibition of macrophage TNF secretion observed
in the presence of ketamine (or MK-801) alone.
Figure 4 depicts results for macrophages stimulated
with vancomycin- or daptomycin-exposed MW2;
responses to antibiotic-exposed LAC were similar
(data not shown).
MRSA MW2 and LAC exposed to MK 801
TNF (pg/mL)
0
5000
10000
15000
20000
25000
30000
35000
0
5000
10000
15000
20000
25000
30000
35000
* *
* *
  Control_MW2
  MW2
  MW2_MK801
  Control_LAC
  LAC
  LAC_MK801
V
A
N
C
O
M
Y
C
I
N
D
A
P
T
O
M
Y
C
I
N
Figure 3 MK-801 inhibited TNF secretion by RAW264.7 murine
macrophages stimulated with antibiotic-treated CA-MRSA
isolates LAC and MW2. LAC or MW2 were added to RAW264.7
cells at a final concentration of 10
5 to 10
7 CFU/mL (retrospective
confirmation) in the presence of either vancomycin at 20 μg/mL
(upper panel) or daptomycin at 20 μg/mL (lower panel). One hour
prior to stimulation, MK-801 (150 μΜ) was added to the indicated
wells. Cells were then incubated for 18 hours; supernatants were
collected and analyzed for TNF content by ELISA. Results are
depicted as means with 95% confidence intervals shown as “error
bars” (See Methods). The “*” indicates significance at p < 0.05.
Control represents the mean TNF production by macrophages not
stimulated with bacteria.
Combinations of MW2 , Ketamine and MK801
TNF (pg/mL)
0
10000
20000
30000
40000
0
10000
20000
30000
40000
**
* * *
**
* * *
1.Control
2.MW2
3.MW2+Ket.
4.MW2+MK801
5.MW2+Ket.+MK801
V
A
N
C
O
M
Y
C
I
N
D
A
P
T
O
M
Y
C
I
N
Figure 4 No additive or synergistic effects of combinations of
MK-801 and ketamine on macrophage TNF secretion, in
response to antibiotic-treated CA-MRSA strain MW2, were seen.
Bacteria were added at a final concentration of 10
5 to10
7 CFU/mL
(retrospective confirmation) in the presence of either vancomycin at
20 μg/mL (upper panel) or daptomycin at 20 μg/mL (lower panel).
One hour prior to stimulation, either ketamine at 100 μM, MK-801 at
150 μΜ, or both were added to the indicated wells. Cells were then
incubated for 18 hours; supernatants were collected and analyzed
for TNF content by ELISA. Lane 1 (control) represents the mean TNF
production by macrophages not stimulated with bacteria. The mean
includes wells exposed to ketamine, MK-801, both ketamine and
MK-801, and neither. In the absence of bacteria, TNF secretion was
minimal and was not affected by ketamine and/or MK-801. Lanes 2
-5 depict mean TNF secretion by macrophages exposed to
vancomycin-treated MW2 alone (lane 2), MW2 + ketamine (lane 3),
MW2 + MK-801 (lane 4), or MW2 + ketamine + MK-801 (lane 5). The
“*” on bars 3, 4, 5 indicates that they are statistically different (p <
0.05) from bars 1 and 2. The “**” on bar 2 indicates significantly
higher TNF production (p < 0.05).
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to antibiotic-treated CA-MRSA bacteria: both ketamine
and a competitive NMDA receptor antagonist, APV, block
this effect
We further examined the role of NMDA receptors in
modulating the macrophage TNF response to the CA-
MRSA bacteria by studying the effects of a competitive
NMDA receptor antagonist, APV, and the effects of
the NMDA substrate itself (Figure 5). We found that
APV (at either 300 μM or 3 mM) also inhibited
macrophage TNF secretion in response to vancomy-
cin-exposed MW2 (p < 0.05, Figure 5). The magnitude
of the inhibition was comparable to that observed with
either ketamine or MK-801 (and, as in the case of
MK-801, was not additive or synergistic with keta-
mine). Furthermore, the addition of the NMDA sub-
strate (30 μM) resulted in a marked augmentation of
the macrophage TNF response to the antibiotic-treated
CA-MRSA bacteria (p < 0.05), and this effect was
blocked by ketamine and by the competitive NMDA
receptor antagonist, APV (Figure 5).
Inhibition of macrophage TNF secretion is observed
across a range of ketamine concentrations and
throughout the incubation period
We next studied the effects of a range of concentra-
tions of ketamine and found that inhibition of macro-
phage TNF secretion in response to vancomycin-
exposed LAC or MW2 was consistently observed at
concentrations of ketamine at the lowest concentration
tested (10 μM) and was greater at concentrations of 50
-150 μM( F i g u r e6 ) .
We also examined the kinetics of inhibition of macro-
phage TNF secretion by incubating RAW264.7 cells for
6, 10, 14, 18 and 24 hours after exposure to ketamine at
a concentration of 100 μM 1 hour prior to stimulation
with vancomycin-exposed LAC or MW2. We found that
the magnitude of suppression of TNF secretion was
similar at all times studied (Figure 7).
Discussion
W ef o u n dt h a te x p o s u r eo fm u r i n em a c r o p h a g e st o
ketamine inhibited TNF secretion by 18-34% after
stimulation with CA-MRSA bacteria in the presence
of antibiotics. The magnitude of the effect was compar-
able in response to both MW2 (USA400) and LAC
(USA300) bacteria and was similar in the presence of
either vancomycin (a lytic antibiotic associated with a
greater TNF response to the bacteria) or daptomycin (a
non-lytic antibiotic associated with a blunted TNF
response to the bacteria). Our data suggest that keta-
mine administration to macrophages stimulated by CA-
MRSA is associated with blunting of the TNF response
to these virulent pathogens, and suggest that these find-
ings may have therapeutic significance in MRSA sepsis.
Furthermore, these data confirm and extend our pre-
vious observations that CA-MRSA bacteria exposed to
daptomycin (versus vancomycin) trigger less TNF secre-
tion by macrophages. The potentially beneficial anti-
inflammatory effects of daptomycin and ketamine were
additive (Figures 2, 3).
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Figure 5 APV inhibited and NMDA augmented TNF secretion
by RAW264.7 murine macrophages stimulated with the
antibiotic-treated CA-MRSA isolate, MW2. Bacteria were added at
a final concentration of 10
5 to10
7 CFU/mL (retrospective
confirmation) in the presence of vancomycin at 20 μg/mL. One
hour prior to stimulation, APV ("low” concentration of 300 μMo r
“high” concentration of 3 mM), ketamine (100 μM), or NMDA (30
μM) were added, alone or in combination, as indicated. Cells were
then incubated for 18 hours; supernatants were collected and
analyzed for TNF content by ELISA. The control lane represents the
mean TNF macrophage production by macrophages not stimulated
with bacteria. The mean includes wells exposed to APV, ketamine,
or NMDA alone or in combination. In the absence of bacteria, TNF
secretion was minimal and was not affected by APV, ketamine, or
NMDA. Lanes 0-9 depict mean TNF secretion by macrophages
exposed to vancomycin-treated MW2 alone (lane 0) or in the
presence of the indicated concentrations of APV, ketamine, and/or
NMDA (lanes 1-9). TNF secretion was reduced by approximately 30-
40% when macrophages were pre-incubated with APV, ketamine, or
APV + ketamine (lanes 1-5). The magnitude of inhibition by
ketamine and high-dose APV was similar and there were no
additive or synergistic effect observed with combinations of
ketamine and APV. Addition of NMDA (30 μΜ) led to a substantial
increase in the amount of TNF secreted in response to the MW2
strain (lane 9), and this augmented response was blocked by both
APV and ketamine. The “*” on “0.Control” and “8.NMDA+lo_APV”
bars indicates significance at p < 0.05. The “**” on “0.Control_MW2”
and “9.NMDA” bars indicates differences between the pretreated
wells, and that TNF production after MRSA stimulation with NMDA
substrate (9.NMDA) is significantly higher than that at the baseline
MRSA stimulation (0.Control_MW2) at p < 0.05.
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sis and other life-threatening infections caused by CA-
MRSA bacteria could expedite the development of novel
strategies for the diagnosis, treatment, and/or prevention
of these serious infections. CA-MRSA infections often
are associated with severe and prolonged host inflamma-
tory responses [43-46]. Prompt antibiotic treatment of
these and other serious bacterial infections is indicated,
but paradoxically has the potential to trigger excessive
release of bacterial products and the subsequent augmen-
tation of the host inflammatory response [15,16]. Macro-
phages are important sources of many of the pro-
inflammatory cytokines (including IL-1b,I L - 6 ,I L - 8 ,
IL-12, and TNF) secreted in response to staphylococci
and other Gram-positive bacteria [15,16,41]. Although
the cytokine cascade is essential for normal host defense,
excessive or inappropriate inflammation can be harmful.
Therefore we need an improved understanding of these
interactions in order to develop better adjunctive thera-
pies for patients with severe bacterial infections.
In a previous study, we found that exposure of either
of two CA-MRSA strains isolated from Memphis chil-
dren (or any of four other S. aureus isolates from
children with invasive staphylococcal infections) to dap-
tomycin (compared with vancomycin) led to a less
pronounced macrophage inflammatory response, charac-
terized by diminished secretion of TNF and reduced
accumulation of the inducible nitric oxide synthase
(iNOS) [11]. In this study, we found that this differential
effect of daptomycin (versus vancomycin) was also
observed when macrophages were stimulated with either
of the two prototypical CA-MRSA strains most widely
studied today: the USA400 isolate, MW2, and the
USA300 isolate, LAC. Importantly, ketamine pre-incuba-
tion inhibited macrophage TNF secretion in response to
both CA-MRSA strains in the presence of daptomycin
as well as in the presence of vancomycin, and the great-
est suppression of TNF secretion was noted in the pre-
sence of both daptomycin and ketamine.
The mechanism(s) responsible for the anti-inflamma-
tory properties of ketamine are not known, but its neu-
rological and psychotropic actions are believed primarily
to be mediated by antagonism of NMDA receptors
[21,47]. Glutamate is the brain’s primary excitatory neu-
rotransmitter. NMDA receptors are found in many cell
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Figure 6 TNF suppression by ketamine was tested at
concentrations of 10 μM, 50 μM, 100 μM and 150 μM in the
presence of vancomycin at 20 μg/mL and RAW264
macrophage stimulation with either LAC (upper panel) or MW2
(lower panel) CA-MRSA strains. Bacteria were added at a final
concentration of 10
5 to10
7 CFU/mL (retrospective confirmation) in
the presence of vancomycin at 20 μg/mL. The inoculation time was
18 hours. Results are depicted as percentile reduction with 95%
confidence intervals shown, i.e., the percent of TNF reduction that
occurs after the specific concentration of ketamine was added.
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Figure 7 TNF suppression by ketamine was tested after 6, 10,
14, 18 and 24 hours exposure in the presence of vancomycin
at 20 μg/mL and RAW264 macrophage stimulation with either
LAC (upper panel) or MW2 (lower panel) CA-MRSA strains.
Bacteria were added at a final concentration of 10
5 to10
7 CFU/mL
(retrospective confirmation) in the presence of vancomycin at 20
μg/mL. The ketamine concentration was 100 μM. Results are
depicted as percentile reduction with 95% confidence intervals, i.e.,
the percent of TNF reduction at the specific exposure time that
occurs in comparison to inoculation without ketamine at the same
time. The “*” indicates statistically significant difference at p < 0.05.
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and multiple hematopoietic precursors in bone marrow
cells [40,42,47,48]. Both ketamine and the chemically
unrelated anticonvulsant dizocilpine (MK-801) are non-
competitive antagonists of the NMDA receptor, one of
the three known glutamate receptors [32,33,47]. APV is
a competitive inhibitor of the classical NMDA receptor
and acts on the NR2 component of the receptor (30, 33).
We found that MK-801 and APV also inhibited
macrophage TNF secretion in response to antibiotic-
treated MW2 or LAC cells. The magnitude of the inhi-
bition by MK-801 (approximately 30%) and APV
(25-35%) was comparable to that observed with keta-
mine (18-34%), and combinations of MK-801 and keta-
mine or of APV and ketamine did not exhibit additive
or synergistic inhibition of TNF secretion. Furthermore,
adding NMDA led to augmented macrophage TNF
secretion in response to antibiotic-treated CA-MRSA
bacteria, and the NMDA receptor antagonist, APV,
blocked this effect. The suppression of TNF induced by
ketamine was observed across a range of concentrations
and throughout the incubation period.
Our study has its limitations. To translate the present
findings, we are currently working on a clinical model to
assess the clinical significance of ketamine’s anti-inflam-
matory effects in patients with bacterial sepsis. Although
studies of the effect of ketamine on macrophage
responses to purified bacterial components such as
Gram-negative lipopolysaccharide (LPS) or Gram-positive
lipoteichoic acid (LTA) are instructive [23,24,49], we
argue that characterization of the macrophage responses
to whole organisms is more likely to provide clinical
insights. Indeed, the pioneering experiments of Carswell
and Old that identified TNF used whole bacteria as sti-
muli in macrophage sepsis simulation settings [49], and
we have previously demonstrated that macrophage
responses to live, antibiotic-treated staphylococci serve as
a powerful model system. Furthermore, the model exam-
ines the effect of ketamine only in the presence of anti-
biotics (either vancomycin or daptomycin). In practice,
this is a common clinical scenario. Our data suggest that
clinically achievable concentrations of both ketamine and
daptomycin could potentially inhibit the excessive macro-
phage inflammatory response that is observed in patients
with severe staphylococcal infections.
Conclusions
In the battle of sepsis everything counts. Adjunctive
therapies of sepsis are greatly needed. Studies in animal
models and clinical trials will be required to determine
whether the anti-inflammatory effects of ketamine and/or
other agents that block NMDA receptors could be bene-
ficial in the treatment of severe staphylococcal infections.
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